2023 World Conference on Lung Cancer (Posters)-EP08.02. Durvalumab as Maintenance in Patients who Received Chemoradiotherapy for Unresectable Stage III NSCLC: RWD from an EAP in Brazil (LACOG 0120)

EP08.02. Durvalumab as Maintenance in Patients who Received Chemoradiotherapy for Unresectable Stage III NSCLC: RWD from an EAP in Brazil (LACOG 0120) - PDF(Slides)

Back to course

Pdf Summary

This document is a summary of an observational retrospective cohort study on the efficacy and safety of durvalumab treatment for unresectable stage III non-small cell lung cancer (NSCLC) in Brazil. The study included patients who had previously completed platinum-based chemotherapy with radiation therapy and showed no evidence of disease progression.<br /><br />The study analyzed various characteristics of the patients, including age, gender, skin color, disease stage, performance status, tumor histologic type, smoking status, previous radiotherapy, previous induction chemotherapy, and best response after chemoradiotherapy.<br /><br />The main reasons for treatment discontinuation before 12 months were disease progression, loss of follow-up, and death due to a second primary tumor. Treatment-related adverse events of any grade occurred in a significant number of patients, with pneumonitis being reported in some cases.<br /><br />The median progression-free survival (PFS) varied depending on the histologic type of the tumor, with adenocarcinoma patients having a longer median PFS compared to squamous cell carcinoma patients. The median time to start durvalumab treatment was 56.5 days, and the median follow-up was 50.3 months.<br /><br />The study also reported the median overall survival (OS) for adenocarcinoma and squamous cell carcinoma patients, with adenocarcinoma patients having a longer median OS. The document includes percentages for the OS rates at different time points.<br /><br />Overall, the study provides insights into the efficacy and safety of durvalumab treatment for unresectable stage III NSCLC. It highlights the importance of considering histologic type when evaluating treatment outcomes and provides information on treatment duration, doses, and adverse events.

Asset Subtitle

Mauro Zukin

Meta Tag

Speaker Mauro Zukin

Topic Local-Regional NSCLC: Multimodality Therapy

Keywords

observational retrospective cohort study

durvalumab treatment

unresectable stage III NSCLC

Brazil

platinum-based chemotherapy

radiation therapy

disease progression

tumor histologic type

treatment-related adverse events

overall survival